Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04203160
Title Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors University of Michigan Rogel Cancer Center
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
University of Arizona Cancer Center Tucson Arizona 85724 United States Details
Northwestern University -- Lurie Comprehensive Cancer Center Chicago Illinois 60611 United States Details
University of Michigan Rogel Cancer Center Ann Arbor Michigan 48109 United States Details
Atlantic Health System Morristown New Jersey 07960 United States Details
University Hospitals - Seidman Cancer Center Cleveland Ohio 44106 United States Details
Allegheny Health Network Pittsburgh Pennsylvania 15224 United States Details
Vanderbilt-Ingram Cancer Center Nashville Tennessee 37232 United States Details
University of Texas Southwestern -- Simmons Comprehensive Cancer Center Dallas Texas 75390 United States Details
Fred Hutch/University of Washington Cancer Consortium Seattle Washington 98109 United States Details
University of Wisconsin - Carbone Cancer Center Madison Wisconsin 53705 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field